Formulary management of eradication therapies for Helicobacter pylori. Drug selection by means of the SOJA method

Disease Management and Health Outcomes

Volumn 7, Issue 5, 2000, Pages 251-266

  Janknegt, Robert ^a   Engels, Leopold G J B ^a  

^a Zuyderland Medical Centre   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

AMOXICILLIN; ANTIINFECTIVE AGENT; BISMUTH; CLARITHROMYCIN; IMIDAZOLE; LANSOPRAZOLE; METRONIDAZOLE; OMEPRAZOLE; PANTOPRAZOLE; PROTON PUMP INHIBITOR; RANITIDINE BISMUTH CITRATE; TETRACYCLINE; TINIDAZOLE;

ANTIBIOTIC RESISTANCE; AREA UNDER THE CURVE; ARTICLE; DIARRHEA; DRUG COST; DRUG EFFICACY; DRUG FORMULARY; DRUG MIXTURE; DRUG TOLERABILITY; ERADICATION THERAPY; GRAM NEGATIVE INFECTION; HEADACHE; HELICOBACTER PYLORI; HUMAN; MEDICAL DECISION MAKING; NAUSEA; NETHERLANDS; OUTCOMES RESEARCH; TASTE DISORDER; VOMITING;

EID: 0034090016     PISSN: 11738790     EISSN: None     Source Type: Journal    
DOI: 10.2165/00115677-200007050-00003     Document Type: Article

References (156)

1. 1. Janknegt R, Steenhoek A. The system of objectified judgement analysis. A tool in rational drug selection for formulary inclusion. Drugs 1997; 53: 550-62
2. 2. Penston JG, McColl KE. Eradication of Helicobacter pylori: an objective assessment of current therapies. Br J Clin Pharmacol 1997; 43: 223-43
3. 3. Wermeille J, Zeiger G, Cunningham M. The eradication treatments of Helicobacter pylori.Pharm World Sci 1998; 20: 1-17
4. 4. Enrech N, Ronchera-Oms CL, Carrera-Hueso FJ. Strategies for treatmenr of Helicobacter pylori infection in gastroduodenal disease. Eur Hosp Pharm 1997; 3: 7-13
5. 5. Williams MP, Pounder RE. What are appropriate end points for Helicobacter pylori eradication in the treatment of duodenal ulcer? Drugs 1998; 56: 1-10
6. 6. Larson C, Cavuto NJ, Flockhart DA, et al. Bioavailability and efficacy of omeprazole given orally and by nasogastric tube. Dig Dis Sci 1996; 41: 475-9
7. 7. Chun AH, Shi HH, Achari R, et al. Lansoprazole: administration of the contents of a capsule dosage formulation through a nasogastric tube. Clin Ther 1996; 18: 833-43
8. 8. Delhotal-Landes B, Cournot A, Vermeire N, et al. The effect of food and antacids on lansoprazole absorption in disposition. Data on file Aventis
9. 9. Bergstrand R, Grind M, Nyberg G, et al. Decreased oral bioavailability of lansoprazle in healthy volunteers when given with a standardised breakfast. Clin Drug Invest 1996; 9: 67-71
10. 10. Gladziwa U, Klotz U. Pharmacokinetics and pharmacodynamics of H2-receptor antagonists in patients with renal insufficiency. Clin Pharmacokinet 1993; 24: 319-32
11. 11. Andersson T, Olsson R, Ragardh CG, et al. Pharmacokinetics of 14C omeprazole in patients with liver cirrhosis. Clin Pharmacokinet 1993; 24: 71-8
12. 12. Morgan MY, Stambuk D. Famotidine pharmacokinetics following oral and iv administration in patients with liver disease: results of a preliminary study. Postgrad Med J 1986; 62 Suppl. 2: 29-37
13. 13. Flouvat B, Delhotal-Landes B, Cournot A, et al. Single and multiple dose pharmacokinetics of lansoprazole in elderly subjects. Br J Clin Pharmacol 1993; 36: 467-9
14. 14. Hussein Z, Granneman GR, Mukherjee D, et al. Age-related differences in the pharmacokinetics and pharmacodynamics of lansoprazole. Br J Clin Pharmacol 1993; 36: 391-8
15. 15. Chang M, Tybring G, Dahl ML, et al. Interphenotype differences in disposition and effect on gastrin levels of omeprazole. Suitability of omeprazole as a probe for CYP2C19. Br J Clin Pharmacol 1995; 39: 511-8
16. 16. Andersson T, Bergstrand R, Cederborg C. Influence of acid secretory status on absorption of omeprazole from enteric coated granules. Br J Clin Pharmacol 1991; 31: 275-8
17. 17. Huber R, Hartmann M, Bliesrath H, et al. Pharmacokinetics of pantoprazole in man. Int J Clin Pharmacol Ther 1996; 34 Suppl. 1: S7-16
18. 18. Schulz HU, Hartmann M, Steinjans VW, et al. Lack of influence of pantoprazole on the disposition kinetics of theophylline in man. Int J Clin Pharmacol Ther 1996; 34 Suppl. 1: S51-7
19. 19. Middle MV, Muller FO, Schall R, et al. No influence of pantoprazole on the pharmacokinetics of phenytoin. Int J Clin Pharmacol Ther 1996; 34 Suppl. 1: S72-5
20. 20. Chu SY, Deaton R, Cavanaugh J. Absolute bioavailability of clarithromycin after oral administration in humans. Antimicrob Agents Chemother 1992; 36: 1147-50
21. 21. Chu SY, Sennello LT, Bunnell ST, et al. Pharmacokinetics of clarithomycin, a new macrolide, afetr single ascending oral doses. Antimicrob Agents Chemother 1992; 36: 2447-53
22. 22. Ralph ED. Clinical pharmacokinetics of metronidazole. Clin Pharmacokinet 1983; 8: 43-62
23. 23. Janknegt R. Antimicrobial Agents. Disease and pharmacokinetics. Amsterdam: Reed, 1994
24. 24. Petersen KU. Review article: omeprazole and the cytochrome P450 system. Aliment Pharmacol Ther 1995; 9: 1-9
25. 25. Meyer UA. Metabolic interactions of the PPIs lansoprazole, omeprazole and pantoprazole wiht other drugs. Eur J Gastroenterol Hepatol 1996; 8 Suppl. 1: S21-5
26. 26. Rizzo N, Padoin C, Palombo S, et al. Omeprazole and lansoprazole are not inducers of cyt4501A2 under conventional therapeutic conditions. Eur J Clin Pharmacol 1996; 49: 491-5
27. 27. Howden CW. Clinical pharmacology of omeprazole. Clin Pharmacokinet 1991; 20: 38-49
28. 28. Zech K, Steinijans VW, Huber R, et al. Pharmacokinetics and drug interactions-relevant factors for the choice of a drug. Int J Clin Pharmacol Ther 1996; 34 Suppl. 1: S3-6
29. 29. Tuynman HA, Festen HP, Rohss K, et al. Lack of effect of antacids on plasma concentrations of omeprazole given as enteric-coated granules. Br J Clin Pharmacol 1987; 24: 833-5
30. 30. Spencer CM, Faulds D. Lansoprazole. A reappraisal of its pharmacodynamic and pharmacokinetic properties, and its therapeutic efficacy in acid-related disorders. Drugs 1994; 48: 404-30
31. 31. Langtry HD, Brogden RN. Clarithromycin. A review of its efficacy in the treatment of respiratory tract infections in immunocompetent patients. Drugs 1997; 53: 973-1004
32. 32. Hansten PD, Horn JR. Drug Interactions. Analysis and Management. Vancouver, Canada: Applied Therapeutics, 1997
33. 33. Gelman CR, Rumack BH, Hutchison TA, editors. Drugdex System. Englewood (CO) USA: Micromedex Inc, 1999 vol. 100
34. 34. Drug Interactions Database. Koninklijke Nederlandse Maatschappij ter Bevordering der Pharmacie, Mar 2000
35. 35. Van Zwet AA, De Boer WA, Schneeberger PM, et al. Prevalence of primary Helicobacter pylori resistance to metronidazole and clarithromycin in The Netherlands. Eur J Clin Microbiol 1996; 15: 861-4
36. 36. Houben MH, van de Beek D, Hensen EF, et al. Helicobacter pylori eradication therapy in the Netherlands. Scand J Gastroenterol 1999; 230 Suppl.: 17-22
37. 37. Van der Wouden EJ, Thijs JC, van Zwet AA, et al. The influence of in-vitro imidazole resistance on the efficacy of nitroimidazole containing anti H. pylori regimens. A mela-analysis. Am J Gastroenterol 1999; 94: 1751-9
38. 38. Houben MH, van der Beek D, Hensen E, et al. A systematic review of Helicobacter pylori eradication therapy. The impact of antimicrobial resistance on eradication rates. Aliment Pharmacol Ther 1999; 13: 1047-55
39. 39. Bazzoli F, Berretti D, De Luca L, et al. What can be learnt from the new data about antibiotic resistance? Are there any practcal consequences of Helicobacter pylori antibiotic resistance? Eur J Gastroenterol Hepatol 1999; 11 Suppl. 2: S39-43
40. 40. Megraud F. Resistance of Helicobacter pylori to antibiotics: the main limitation of current proton-pump inhibitor triple therapy. Eur J Gastroenterol Hepatol 1999; 11 Suppl. 2: S35-7
41. 41. Rinaldi V, Zullo A, De Francesco V, et al. Helicobacter pylori eradication with proton pump inhibitor-based triple therapies and re-treatment with raniditidine bismuth citrate-based triple therapy. Aliment Pharmacol Ther 1999; 13: 163-8
42. 42. Muller P, Simon B. Helicobacter pylori eradikation: modifizierte tripel-therapie mit Lansoprazol. Fortschr Med 1996; 114: 497-9
43. 43. Spinzi GC, Bierti L, Bortoli A, et al. Comparison of omeprazole and lansoprazole in short-term triple therapy for Helicobacter pylori infection. Aliment Pharmacol Ther 1998; 12: 433-8
44. 44. Ducons JA, Santolaria S, Guirao R, et al. Impact of clarithromycin resistance on the effectiveness of a regimen for Helicobacter pylori: a prospective study of 2-week lansoprazole, amoxycillin and clarithromycin in active peptic ulcer. Aliment Pharmacol Ther 1999; 13: 775-80
45. 45. Sieg A, SellingerM, Schlauch D, et al. Short-term therapy with lansoprazole 30 mg or 60 mg, amoxycillin and clarithromycin to eradicate H. pylori. Aliment Pharmacol Ther 1999; 13: 865-8
46. 46. Moayyedi P, Langworthy H, Shanahan K, et al. Comparison of one and two weeks of lansoprazole, amoxicillin and clarithromycin in the treatment of H. pylori. Helicobacter 1996; 1: 71-4
47. 47. Lind T, Megraud F, Unge P, et al. The MACH2 study: role of omeprazole in eradication of Helicobacter pylori with 1-week triple therapies. Gastroenterol 1999; 116: 248-53
48. 48. Catalanbo F, Catanzaro R, Bentivegna C, et al. Ranitidine bismuth citrate versus omeprazole triple therapy for the eradication of Helicobacter pylori and healing of duodenal ulcer. Aliment Pharmacol Ther 1998; 12: 59-62
49. 49. Sung JJ, Leung WK, Ling TK, et al. One-week use of ranitidine bismuth citrate, amoxycillin and clarithromycin for the treatment of Helicobacter pylori-related duodenal ulcer. Aliment Pharmacol Ther 1998; 12: 725-30
50. 50. Laine L, Frantz JE, Baker A, et al. A US multicentre trial of dual and proton pump inhibitor-based triple therapies for Helicobacter pylori. Aliment Pharmacol Ther 1997; 11: 913-7
51. 51. Laine L, Estrada R, Trujillo M, et al. Randomized comparison of differing periods of twice-a-day triple therapy for the eradication of Helicobacter pylori. Aliment Pharmacol Ther 1996; 10: 1029-33
52. 52. Lind T, Veldhuyzen van Santen S, Unge P, et al. Eradication of Helicobacter pylori using one-week triple therapies combining omeprazole with two antimicrobials: the MACH 1 study. Helicobacter 1996; 1: 138-44
53. 53. Pieramico O, Zanetti MV, Innerhofer M, et al. Omeprazole-based dual and triple therapy for the treatment of Helicobacter pylori infection in peptic ulcer disease: a randomized trial. Helicobacter 1997; 2: 92-7
54. 54. Bigard MA, Delchier JC, Riachi G, et al. One-week triple therapy using omeprazole, amoxycillin and clarithromycin for the eradication of Helicobacter pylori in patients with non-ulcer dyspepsia: influence of dosage of omeprazole and clarithromycin. Aliment Pharmacol Ther 1998; 12: 383-8
55. 55. Lee JM, Breslin NP, Hyde DK, et al. Treatment options for Helicobacter pylori infection when proton pump inhibitir-based triple therapy fails in clinical pracitce. Aliment Pharmacol Ther 1999; 13: 489-96
56. 56. Malfettheiner P, Bayerdoerffer E, Diete U, et al. The GU-MACH study: the effect of 1-week omeprazole triple therapy on Helicobacter pylori infection in patients with gastric ulcer. Aliment Pharmacol Ther 1999; 13: 703-12
57. 57. Calvet X, Lopez-Lorieme MT, Cubells MJ, et al. Two week dual vs. one week triple therapy for cure of Helicobacter pylori infection in primary care: a multicentre, randomized trial. Aliment Pharmacol Ther 1999; 13: 781-6
58. 58. Martin Mir ML, Val J, Fuentes J, et al. Effectiveness of the eradication of H. pylori by treatment with omeprazole, amoxicillin and clarithromycin according to dosage and administration schedule. Gastroenterol Hepatol 1998; 21: 432-6
59. 59. Fock KM, Chelvam P, Lim SG. Triple therapy in the eradication of H. pylori in patients with duodenal ulcer disease: results of a multicentre study in SE Asia. Aliment Pharmacol Ther 2000; 14: 225-31
60. 60. Baena Diez JM, Sancho Perpinan A, Lopez Mompo C, et al. Treatment with omeprazole, elarithromycin and amoxicillin for one week. Their efficacy and tolerance in eradicating H. pylori in primary care. Aten Prim 1998; 22: 547-51
61. 61. Zanten SJ, Bradette M, Farley A, et al. The DU-MACH study: eradication of H. pylori and ulcer healing in patients with acute duodenal ulcer using omeprazole based triple therapy. Aliment Pharmacol Ther 1999; 13: 289-95
62. 62. Labenz J, Stolte M, Peitz U, et al. One-week triple therapy with omeprazole, amoxycillin and either clarithromycin or metronidazole for cure of Helicobacter pylori infection. Aliment Pharmacol Ther 1996; 10: 207-10
63. 63. Yousfi MM, EL-Zimaity HM, Genta RM, et al. One-week triple therapy with omeprazole, amoxycillin and claritromycin for treatment of H. pylori infection. Aliment Pharmacol Ther 1996; 10: 617-21
64. 64. Katoh M, Asaka M, Kudoh M, et al. Clinical efficacy of lansoprazole in eradication of Helicobacter of Helicobacter pylori. J Clin Gastroenterol 1995; 20 Suppl. 2: S112-4
65. 65. Abdul Ai GM, Dajani AI, Nounou M, et al. Resolution of gastritis induced by Helicobacter pylori 4-5 weeks after succesful eradication of infection using a triple therapy of pantoprazole, amoxicillin and clarithromycin for one week. Digestion 1999; 60: 286-8
66. 66. Lamouliatte H, Samoyeau R, De Mascarel A, et al. Double vs single dose of pantoprazole in combination with clarithromycin and amoxycillin for 7 days, in eradication of H. pylori in patients with non-ulcer dyspepsia. Aliment Pharmacol Ther 1999; 13: 1523-30
67. 67. De Boer WA, Haeck PW, Otten MJ, et al. Optimal treatment of Helicobacter pylori with ranitidine bismuth citrate: a randomized comparison between two 7-day triple therapies and a 14 day dual therapy. Am J Gastroenterol 1998; 93: 1101-7
68. 68. Ricciardello L, Cannizaro O, D'Angelo A, et al. Efficacy and safety of three 7-day Helicobacter pylori eradication regimens containing ranitidine bismuth citrate. Aliment Pharmacol Ther 1998; 12: 533-7
69. 69. Sung JJ, Chan FK, Wu JC, et al. One-week ranitidine bismuth citrate in combinations with metronidazole, amoxycillin and clarithromycin in the treatment of H. pylori infection: the RBC MACH study. Aliment Pharmacol Ther 1999; 13: 1079-84
70. 70. Misiewicz JJ, Harris AW, Bardhan KD, et al. One week triple therapy for Helicobacter pylori: a multicentre comparative study. Gut 1997; 41: 735-9
71. 71. Labenz J, Stolte M, Ruehl GH, et al. One-week low-dose triple therapy for the eradication of Helicobacter pylori infection. Eur J Gastroenterol Hepatol 1995; 7: 9-11
72. 72. Peterson WL, Ciociola AA, Sykes D, et al. Ranitidine bismuth citrate plus clarithromycin is effective for healing duodenal ulcers, eradicating H. pylori and reducing ulcer recurrence. Aliment Pharmacol Ther 1996; 10: 251-61
73. 73. Prach AT, Malek M, Tavakoli M, et al. H2-antagonist maintenance therapy versus Helicobacter eradication in patients with chronic duodenal ulcer disease; a prospective study. Aliment Pharmacol Ther 1998; 12: 873-80
74. 74. Bayerdoerffer E, Lind T, Dite P, et al. Omeprazole, amoxycillin and metronidazole for the cure of H. pylori infection. Eur J Gastroenterol Hepatol 1999; 11 Suppl. 2: S19-22
75. 75. Gisbert JP, Boixeda D, Martin de Argila C, et al. New one-week triple therapies with metronidazole for the eradication of H. pylori: clarithromycin or amoxycillin as the second antibiotic. Med Clin (Bare) 1998; 110: 1-5
76. 76. Kolkman JJ, Tan TG, Oudkerk Pool M, et al. Ranitidine bismuth citrate with clarithromycin versus omeprazole with amoxicillin in the cure of Helicobacter pylori infection. Aliment Pharmacol Ther 1997; 11: 1123-9
77. 77. Bertoni G, Sassatelli R, Nigrisoli E, et al. Triple therapy with azithromycin, omeprazole and amoxicillin is highly effective in the eradication of Helicobacter pylori: a controlled trial versus omeprazole plus amoxicillin. Am J Gastroenterol 1996; 91: 259-63
78. 78. Rinaldi V, Zullo A, Pugliano F, et al. The management of failed dual or triple therapy for Helicobacter pylori eradication. Aliment Pharmacol Ther 1997; 11: 929-33
79. 79. Spinzi G, Bortoli A, Colombo E, et al. Randomized study comparing omeprazole plus amoxycillin versus omeprazole plus clarithromycin for eradication of Helicobacter pylori. Aliment Pharmacol Ther 1997; 11: 317-22
80. 80. Zullo A, Rinaldi V, Pugliano F, et al. Omeprazole plus clarithromycin and either tinidazole or tetracycline for Helicobacter pylori infection: a randomized prospective study. Am J Gastroenterol 1997; 92: 2029-31
81. 81. Pommerien W, Schultze V, Braden B, et al. Dose-response of omeprazole combined with amoxycillin on duodenal ulcer healing and eradication of Helicobacter pylori. Aliment Pharmacol Ther 1996; 10: 303-8
82. 82. Labenz J, Ruhl GH, Bertrams J, et al. Medium-or high-dose omeprazole plus amoxicillin eradicates Helicobacter pylori in gastric ulcer disease. Am J Gastroenterol 1994; 89: 726-30
83. 83. Labenz J, Boersch G, Gyenes E, et al. Amoxicilin plus omeprazole: a simple and effective therapeutic regimen to eradicate Helicobacter pylori. Eur J Gastroenterol Hepatol 1993; 5: 115-6
84. 84. Gabryelewicz A, Laszewicz W, Dzieniszewski J, et al. Multicenter evaluation of dual therapy (omeprazole and amoxycillin) for Helicobacter pylori-associated duodenal and gastric ulcer. J Physiol Pharmacol 1997; 48 Suppl. 4: 93-105
85. 85. Ciok J, Dzieniszewski J, Lucer C. Helicobacter pylori eradication and antral intestinal metaplasia. Two years follow up study. J Physiol Pharmacol 1997; 48 Suppl. 4: 115-22
86. 86. Tusri A, Cammarota G. Papa A, et al. One-week low-dose triple therapy vs two-week medium-dose double-therapy for H. pylori infection. Hepatogastroenterol 1996; 43: 859-62
87. 87. Tursi A, Cammarota G, Montalto M, et al. Evaluation of the efficacy and tolerability of four different therapeutic regimens for the H. pylori eradication. Panminerva Med 1996; 38: 145-9
88. 88. Zullo A, Rinaldi V, Meddi P, et al. H. pylori eradication wirh dual and low-dose triple therapy in patients with liver cirrhosis. Ital J Gastrenterol Hepatol 1999; 31: 831-5
89. 89. Chiba N. Omeprazole and clarithromycin with and without metronidazole for the eradication of Helicobacter pylori. Am J Gastroenterol 1996; 91: 2139-43
90. 90. Goddard AF, Spiller RC. Helicobacter pylori eradication in clinical practice: one-week low-dose triple therapy is preferable to classical bismuth based triple therapy. Aliment Pharmacol Ther 1996; 10: 1009-13
91. 91. Goddard AF, Logan RPH, Lawes S, et al. Randomized controlled comparison of nitroimidazoles for the eradication of Helicobacter pylori and relief of ulcer-associated and non-ulcer dyspepsia. Aliment Pharmacol Ther 1999; 13: 637-42
92. 92. Treiber G, Ammon S, Schneider E, et al. Amoxicillin/metronidazole/omeprazole/clarithromycin: a new, short quadruple therapy for Helicobacter pylori eradication. Helicobacter 1998; 3: 54-8
93. 93. Tanimura H, Kawano S, Kubo M, et al. Does Helicobacter pylori eradication depend on the period of amoxicillin treatment? A retrospective study. J Gastroenterol 1998; 33: 23-6
94. 94. Houhen MH, Hensen EF, Rauws EA, et al. Randomized trial of omeprazole and clarithomycin combioned with either metronidazole or amoxycillin in patients with metronidazole resistant of - susceptible H. pylori strains. Aliment Pharmacol Ther 1999; 13: 883-9
95. 95. Batovsky M, Paulen P, Valko L, et al. Effect and tolerance of eradication treatment of H. pylori infection by proton pump blockers in combination with clarithromycin and metronidazole in patients with functional gastric dyspepsia. Cesk Gastroenterol Vyz 1999; 53: 99-103
96. 96. Chiba N, Marshall CP. Omeprazole once or twice daily with clarithromycin and metronidazole for H. pylori. Can J Gastroenterol 2000; 14: 27-31
97. 97. Van der Wouden EJ, Thijs JC, van Zwet AA, et al. One-week triple therapy with ranitidine bismuth citrate, clarithromycin and metronidazole versus two week dual therapy with ranitidine bismuth citrate and clarithromycin for Helicobacter pylori infection: a randomized, clinical trial. Am J Gastroenterol 1998; 93: 1228-31
98. 98. Hoffmann JS, Katz LM, Case DR. Efficacy of a 1-week regimen of ranitidine bismuth citrate in combination with metronidazole and clarithromycin for Helicobacter pylori eradication. Aliment Pharmacol Ther 1999; 13: 503-6
99. 99. Wouden van der EJ, Thijs JC, van Zwet AA, et al. The influence of metronidazole resistance on the efficacy of ranitidine bismuth citrate triple therapy regimens for Helicobacter pylori infection. Aliment Pharmacol Ther 1999; 13: 297-302
100. 100. Chey WD, Fisher L, Barnett J, et al. Low-versus high-dose azithromycin triple therapy for Helicobacter pylori infection. Aliment Pharmacol Ther 1998; 12: 1263-7
101. 101. Logan RP, Bardhan KD, Celestin LR, et al. Eradication of Helicobacter pylori and prevention of recurrence of duodenal ulcer: a randomized, double-blind multi-centre trial of omeprazole with or without clarithromycin. Aliment Pharmacol Ther 1995; 9: 417-23
102. 102. Logan RP, Gummett PA, Schaufelberger HD, et al. Eradication of Helicobacter pylori with clarithromycin and omeprazole. Gut 1994; 35: 323-6
103. 103. Sonnenberg A, Olsen CA, Zhang J. The effect of antibiotic therapy on bleeding from duodenal ulcer. Am J Gastroenterol 1999; 94: 950-4
104. 104. Caselli M, Trevisani L, Tursi A, et al. Short-term, low-dose triple therapy with azithromycin, metronidazole and lansoprazole appears highly effective for the eradication of Helicobacter pylori. Eur J Gastroenterol Hepatol 1997; 9: 45-8
105. 105. Dalla Libera M, Pazzi P, Carli GG, et al. High effeciveness and safety of one-week antibiotic regimen in Helicobacter pylori eradication. Aliment Pharmacol Ther 1996; 10: 203-6
106. 106. Bazzoli F, Zagari RM, Fossi S, et al. Short term low-dose triple therapy for the eradication of Helicobacter pylori. Eur J Gastroenterol Hepatol 1994; 6: 773-7
107. 107. Tursi A, Cammarotta G, Montalto M, et al. Low-dose omeprazole plus clarithromycin and either tinidazole or amoxycillin for Helicobacter pylori infection. Aliment Pharmacol Ther 1996; 10: 285-8
108. 108. Bazzoli F, Zagari M, Pozzato P, et al. Evaluation of short-term low-dose triple therapy for the eradication of H. pylori by factorial design in a randomized, double-blind, controlled study. Aliment Pharmacol Ther 1998; 12: 439-45
109. 109. Moayyedi P, Sahey P, Tompkins DS, et al. Efficacy and optimum dose of omeprazole in a new-1-week triple therapy regimen to eradicate Helicobacter pylori. Eur J Gastroenterol Hepatol 1995; 7: 835-40
110. 110. Trevisani L, Sartori S, Caselli M, et al. A four-day low dose triple therapy regimen for the treatment of H. pylori infection. Am J Gastroenterol 1998; 93: 390-3
111. 111. Jaup BH, Norrby A, Low dose, short-term triple therapy for cure of Helicobacter pylori infection and healing of peptic ulcers. Am J Gastroenterol 1995; 90: 943-5
112. 112. Spadaccini A, De Fanis C, Sciampa G, et al. Omeprazole versus ranitidine: short-term triple therapy in patients with Helicobacter pylori-positive duodenal ulcers. Aliment Pharmacol Ther 1996; 10: 829-31
113. 113. Moshkowitz M, Konikoff FM, Peled Y, et al. One week triple therapy with omeprazole, clarithromycin and tinidazole for Helicobacter pylori: differing efficacy in previously treated and untreated patients. Aliment Pharmacol Ther 1996; 10: 1015-9
114. 114. Sito E, Konturek P, Bielanski W, et al. One week treatment with omeprazole, clarithromycin and tinidazole or lansoprazole, amoxycillin and metronidazole for cure of Helicobacter pylori infection in duodenal ulcer patients. J Physiol Pharmacol 1996; 47: 221-8
115. 115. Axon AT, Ireland A, Lancaster Smith MJ, et al. Ranitidine bismuth citrate and clarithromycin twice daily in the eradication of Helicobacter pylori. Aliment Pharmacol Ther 1997; 11: 81-7
116. 116. Bardhan KD, Wurzer H, Marcelino M, et al. Ranitidine bismuth citrate with clarithromycin given twice daily effectively eradicates Helicobacter pylori and heals duodenal ulcers, Am J Gastroenterol 1998; 93: 380-5
117. 117. Cestari R. Ranitidine bismuth citrate based triple therapy for 7 days is more effective than ranitidine bismuth citrate plus clarithomycin for 14 days in dyspeptic patients with Helicobacter pylori infection. Aliment Pharmacol Ther 1998; 12: 991-6
118. 118. Laine L, Estrada R, Trujillo M, et al. Randomized comparison of ranitidine bismuth citrate-based triple therapies for Helicobacter pylori. Am J Gastroenterol 1997; 92: 2213-5
119. 119. Pozzato P, Zagari M, Cardelli A, et al. Ranitidine bismuth citrate-plus clarithromycin 7-day regimen is effective in eradicating Helicobacter pylori in patients with duodenal ulcer. Aliment Pharmacol Ther 1998; 12: 447-51
120. 120. Stone MA, Patel H, Panja KK, et al. Results of Helicobacter pylori screening and eradication in a multi-ethnic community in central England. Eur J Gastroenterol Hepatol 1998; 10: 957-62
121. 121. Gudjonsson H, Bardhan KD, Hoie O, et al. High Helicobacter pylori eradication rate with a 1-week regimen containing ranitidine bismuth citrate. Aliment Pharmacol Ther 1998; 12: 1113-9
122. 122. Schwarz H, Perschy TB, McSorley DJ, et al. Twice-daily versus thrice-daily clarithromycin in combination with ranitidine bismuth citrate in the eradication of Helicobacter pylori. Helicobacter 1999; 4: 121-7
123. 123. Pare P, Farley A, Romaozinho JM, et al. Comparison of ranitidine bismuth citrate plus clarithromycin with omeprazole plus clarithromycin for the eradication of H. pylori. Aliment PharmacolTher 1999; 13: 1071-8
124. 124. NIH consensus development panel on Helicobacter pylori in peptic ulcer disease. JAMA 1994; 272: 65-9
125. 125. Rauws EAJ, Tytgat GNJ. Helicobacter pylori in duodenal and gastric ulcer disease. Baillieres Clin Gastroenterol 1995; 3: 529-47
126. 126. Graham DY, Hepps KS, Ramirez FC, et al. Treatment of Helicobacter pylori reduces the rate of rebleeding in peptic ulcer disease. Scand J Gastroenterol 1993; 28: 939-42
127. 127. Aalykke C, Lauritsen JM, Hallas J, et al. Helicobacter pylori and risk of ulcer bleeding among users of NSAIDs: a case-control study. Gastroenterol 1999; 116: 1305-9
128. 128. Chan FKL, Sung JJY, Chung SCS. Randomized trial of eradication of H. pylori before NSAID therapy to prevent peptic ulcers. Lancet 1997; 350: 975-9
129. 129. Hawkey CJ. Is Helicobacter pylori eradication useful in patients taking NSAIDs? Eur J Gastroenterol Hepatol 1999; 11 Suppl. 2: S47-50
130. 130. Taal BG, Boot H, van Heerder P, et al. Primary non-Hodgkin lymphoma of the stomach: high grade malignancy in relation to the MALT concept. Gut 1996; 39: 556-61
131. 131. Labenz J, Blum AL, Bayerdorffer E, et al. Curing H. pylori infection in patients with duodenal ulcer may provoke reflux oesophagitis. Gastroenterol 1997; 113: 1442-7
132. 132. Kuipers EJ, Lundell L, Klinkenberg-Knol EC. Atrophic gastritis and H. pylori infection in patients with reflux oesophagitis treated with omeprazole or fundoplication. N Engl J Med 1996; 334: 1018-22
133. 133. Lundell L, Miettinen P, Myrvold HE, et al. Lack of effect of acid suppression on gastric atrophy. Gastroenterol 1999; 117: 319-26
134. 134. Pounder RE, Williams MP. Omeprazole and accelerated onset on atrophic gastritis. Gastroenterol 2000; 118: 238-9
135. 135. McColl KE, Murray LS, Gillen D. Omeprazole and accelerated onset on atrophic gastritis. Gastroenterol 2000; 118: 239-40
136. 136. Kuipers EJ, Klinkenberg-Knol EC, Meuwissen SG. Omeprazole and accelerated onset on atrophic gastritis. Gastroenterol 2000; 118: 240-1
137. 137. Schenk BE, Kuipers EJ, Nelis GF, et al. Effect of H. pylori eradication on the development of chronic gastritis during omeprazole therapy. Gut. In press
138. 138. Jaakkimainen RL, Boyle E, Tudiver F. Is Helicobacter pylori associated with non-ulcer dyspepsia and will eradication improve symptoms? A meta-analysis. BMJ 1999; 319: 1040-4
139. 139. Talley NJ, Vakil N, Ballard D, et al. Absence of benefit of eradicating H. pylori in patients with nonulcer dyspepsia. N Engl J Med 1999; 341: 1106-11
140. 140. Blum AL, Talley NJ, O'Morain C. Lack of effect of treating H. pylori infection in patients with non-ulcer dyspepsia. N Engl J Med 1998; 339: 1875-81
141. 141. Talley NJ, Janssens J, Lauritsen K. Eradication of h. pylori in functional dyspepsia: randomised double-blind placebo controled trial with 12 months' follow-up. BMJ 1999; 338: 833-7
142. 142. McColl K, Murray L, El-Omar E. Symptomatic benefit from eradicating H. pylori infection in patients with nonulcer dyspepsia. N Engl J Med 1998; 339: 1869-74
143. 143. Greenberg PD, Cello JP. Lack of effect of treatment for Helicobacter pylori on symptoms of nonulcer dyspepsia. Arch Intern Med 1999; 159: 2283-8
144. 144. Tan AC, den Hartog G, Mulder CJ. Eradication of H. pylori does not decrease the long-term use of acid-suppressive medication. Aliment Pharmacol Ther 1999; 13: 1519-22
145. 145. Gisbert JP, Boixmeda D, Bermejeo P, et al. Re-treatment after Helicobacter pylori eradication failure. Eur J Gastroenterol Hepatol 1999; 11: 1049-54
146. 146. Gisbert JP, Gisbert JL, Marcos S, et al. Seven-day rescue therapy after Heliobacter pylori treatment failure: omeprazole, bismuth, tetracycline and metronidazole vs ranitidine bismuth citrate, tetracycline and metronidazole. Aliment Pharmacol Ther 1999; 13: 1311-6
147. 147. Gasberrini A, Ojetti V, Armuzzi A, et al. Efficacy of a multistep strategy for H. pylori eradcation. Aliment Pharmacol Ther 2000; 14: 79-83
148. 148. Chan FK, Sung JJ, Suen R, et al. Salvage therapies after failure of H. pylori eradication with ranitidine bismuth citrate-based therapies. Aliment Pharmaol Ther 2000; 14: 91-5
149. 149. Huang JQ, Hunt RH. Treatment after failure. The problem of non-responders. Gut 1999; 45 Suppl. 1: 140-4
150. 150. Unge P. What other regimens are under investigation to treat Helicobacter pylori infection? Gastroenterol 1997; 113: S131-48
151. 151. Van der Hulst RWM, Keller JJ, Rauws EAJ, et al. De behandeling van Helicobacter pylori infectie. Ned Tijdschr Genceskd 1996; 140: 967-70
152. 152. Pipkin GA, Williamson R, Wood JR. Review article: one-week clarithromycin triple therapy regimens for eradication of Helicobacter pylori. Aliment Pharmacol Ther 1998; 12: 823-37
153. 153. Markham A, McTavish D. Clarithromycin and omeprazole. As Helicobacter pylori eradication therapy in patients with H. pylori-associated gastric disorders. Drugs 1996; 51: 161-78
154. 154. Van der Hulst RWM, Keller JJ, Rauws BAJ, et al. Treatment of Helicobacter pylori infection: a review of world literature. Helicobacter 1996; 1: 6-19
155. 155. Laheij RJ, van Rossum LG, Janssen JB, et al. Evaluation of treatment regimens to cure Helicobacter pylori infection. A meta analysis. Aliment Pharmacol Ther 1999; 13: 857-64
156. 156. Ofman JJ, Etchason J, Alexander W, et al. The quality of care of Medicare patients with peptic ulcer disease. Am J Gastroentcrol 2000; 95: 106-13